- Home
- RYOJ vs STTK Comparison
RYOJ vs STTK Comparison
Compare RYOJ & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYOJ
- STTK
- Stock Information
- Founded
- RYOJ 2015
- STTK 2016
- Country
- RYOJ Japan
- STTK United States
- Employees
- RYOJ N/A
- STTK N/A
- Industry
- RYOJ Professional Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RYOJ Consumer Discretionary
- STTK Health Care
- Exchange
- RYOJ Nasdaq
- STTK Nasdaq
- Market Cap
- RYOJ 32.5M
- STTK 38.4M
- IPO Year
- RYOJ 2025
- STTK 2020
- Fundamental
- Price
- RYOJ N/A
- STTK $1.02
- Analyst Decision
- RYOJ
- STTK Hold
- Analyst Count
- RYOJ 0
- STTK 5
- Target Price
- RYOJ N/A
- STTK $2.00
- AVG Volume (30 Days)
- RYOJ 348.0K
- STTK 5.2M
- Earning Date
- RYOJ 01-01-0001
- STTK 08-14-2025
- Dividend Yield
- RYOJ N/A
- STTK N/A
- EPS Growth
- RYOJ 72.91
- STTK N/A
- EPS
- RYOJ 0.13
- STTK N/A
- Revenue
- RYOJ $11,576,848.00
- STTK $2,997,000.00
- Revenue This Year
- RYOJ N/A
- STTK N/A
- Revenue Next Year
- RYOJ N/A
- STTK N/A
- P/E Ratio
- RYOJ $21.69
- STTK N/A
- Revenue Growth
- RYOJ 5.60
- STTK N/A
- 52 Week Low
- RYOJ $2.41
- STTK $0.69
- 52 Week High
- RYOJ $3.75
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- RYOJ N/A
- STTK 62.53
- Support Level
- RYOJ N/A
- STTK $0.71
- Resistance Level
- RYOJ N/A
- STTK $1.07
- Average True Range (ATR)
- RYOJ 0.00
- STTK 0.10
- MACD
- RYOJ 0.00
- STTK 0.03
- Stochastic Oscillator
- RYOJ 0.00
- STTK 70.32
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.